It all really depends on whether Biota is able to break the exclusive licensing rights.
It is actually a double edged sword for GSK. If they say Relenza is not worth anything, Biota can terminate the licensing deal and GSK wont have a leg to stand on for damages.
GSK will be expecting to pay damages, big enough to stop Biota terminating the licensing contract.
All licenses have termination clauses. Even Roche is at risk of having its Tamiful license terminated...
BTA Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
